Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency

Arthritis and Rheumatism

Volumn 54, Issue 7, 2006, Pages 2306-2313

  Schneiders, Marit S ^a   Houten, Sander M ^a   Turkenburg, Marjolein ^a   Wanders, Ronald J A ^a   Waterham, Hans R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPOPROTEIN; MESSENGER RNA; MEVALONATE KINASE; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; ZARAGOZIC ACID A;

ARTICLE; AUTOINFLAMMATORY DISEASE; BIOSYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REGULATION; FIBROBLAST; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; MEVALONATE KINASE DEFICIENCY; PRIORITY JOURNAL; SKIN FIBROBLAST;

BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE; FAMILIAL MEDITERRANEAN FEVER; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULIN D; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RNA, MESSENGER; SIMVASTATIN; SQUALENE; TERPENES; TRICARBOXYLIC ACIDS;

EID: 33745880106     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21960     Document Type: Article

References (30)

1. Drenth JP, Haagsma CJ, van der Meer JW, and the International Hyper-IgD Study Group. Hyperimmunoglobulinemia D and periodic fever syndrome: the clinical spectrum in a series of 50 patients. Medicine (Baltimore) 1994;73:133-44.
2. Hoffmann GF, Charpentier C, Mayatepek E, Mancini J, Leichsenring M, Gibson KM, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993;91:915-21.
3. Hoffmann G, Gibson KM, Brandt IK, Bader PI, Wappner RS, Sweetman L. Mevalonic aciduria: an inborn error of cholesterol and nonsterol isoprene biosynthesis. N Engl J Med 1986;314:1610-4.
4. Houten SM, Koster J, Romeijn GJ, Frenkel J, Di Rocco M, Caruso U, et al. Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome. Eur J Hum Genet 2001;9:253-9.
5. Cuisset L, Drenth JP, Simon A, Vincent MF, van der Velde V, van der Meer JW, et al. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur J Hum Genet 2001;9:260-6.
6. Houten SM, Kuis W, Duran M, de Koning TJ, Royen-Kerkhof A, Romeijn GJ, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999;22:175-7.
7. Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser SD, de Jong JG, et al, and the International Hyper-IgD Study Group. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Genet 1999;22:178-81.
8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
9. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-40.
10. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31.
11. Sakakura Y, Shimano H, Sone H, Takahashi A, Inoue N, Toyoshima H, et al. Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem Biophys Res Commun 2001;286:176-83.
12. Houten SM, Frenkel J, Rijkers GT, Wanders RJ, Kuis W, Waterham HR. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002;11:3115-24.
13. Houten SM, Schneiders MS, Wanders RJ, Waterham HR. Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients. J Biol Chem 2003;278:5736-43.
14. Frenkel J, Rijkers GT, Mandey SH, Buurman SW, Houten SM, Wanders RJ, et al. Lack of isoprenoid products raises ex vivo interleukin-1β secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2002;46:2794-803.
15. Hoffmann GF, Brendel SU, Scharfschwerdt SR, Shin YS, Speidel IM, Gibson KM. Mevalonate kinase assay using DEAE-cellulose column chromatography for first-trimester prenatal diagnosis and complementation analysis in mevalonic aciduria. J Inherit Metab Dis 1992;15:738-46.
16. Hogenboom S, Romeijn GJ, Houten SM, Baes M, Wanders RJ, Waterham HR. Absence of functional peroxisomes does not lead to deficiency of enzymes involved in cholesterol biosynthesis. J Lipid Res 2002;43:90-8.
17. Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 2003;339:62-6.
18. Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003;60:1118-34.
19. Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG, et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci U S A 1993;90:80-4.
20. Simon A, Drewe E, van der Meer JW, Powell RJ, Kelley RI, Stalenhoef AF, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004;75:476-83.
21. Vaidya S, Bostedor R, Kurtz MM, Bergstrom JD, Bansal VS. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch Biochem Biophys 1998;355:84-92.
22. Bostedor RG, Karkas JD, Arison BH, Bansal VS, Vaidya S, Germershausen JI, et al. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J Biol Chem 1997;272:9197-203.
23. Keller RK. Squalene synthase inhibition alters metabolism of nonsterols in rat liver. Biochim Biophys Acta 1996;1303:169-79.
24. Lopez D, Chambers CM, Keller RK, Ness GC. Compensatory responses to inhibition of hepatic squalene synthase. Arch Biochem Biophys 1998;351:159-66.
25. Baxter A, Fitzgerald BJ, Hutson JL, McCarthy AD, Motteram JM, Ross BC, et al. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem 1992;267:11705-8.
26. Sharma A, Slugg PH, Hammett JL, Jusko WJ. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol 1998;38:1116-21.
27. Sharma A, Slugg PH, Hammett JL, Jusko WJ. Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm Res 1998;15:1782-6.
28. Haas D, Kelley RI, Hoffmann GF. Inherited disorders of cholesterol biosynthesis. Neuropediatrics 2001;32:113-22.
29. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in 2 patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51.
30. Arkwright PD, McDermott MF, Houten SM, Frenkel J, Waterham HR, Aganna E, et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 2002;130:484-8.